Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues.
Mammary tumours are the most common neoplasias of female dogs and may have a complex histological pattern with both epithelial and spindle cells participating in the transformation process. A frequent feature of these tumours is chondroid or bone metaplasia of the extracellular matrix, which mainly occurs in areas of proliferated spindle-shaped cells, probably of myoepithelial origin. The present study evaluates immunohistochemically the expression of tenascin in 186 surgical samples of canine mammary tissues, ranging from normality to neoplasia. Tenascin was present in all mammary tissues studied, with an increased expression in remodelling situations and in neoplastic lesions. Basement membrane was the most frequently labelled structure, but stromal tissue was more often and widely labelled in neoplastic lesions. The extracellular matrix was positive in solid and anaplastic carcinomas as well as in spindle cell proliferation areas. Tenascin expression in extracellular matrix was also abundant in areas of initial chondroid metaplasia and, with variable extension, in almost all cartilage islands of mixed tumours. In well differentiated secretory areas only apical granules of luminal cells were positive, suggesting a different pattern of tenascin expression during secretory differentiation. The digestion of chondroitin sulphate significantly improved the labelling for tenascin when a co-expression of these two molecules was present. Although our results suggest that tenascin cannot be used as a marker of transformation or of malignancy in canine mammary oncology, it is clear that this molecule plays an important role in proliferation and differentiation processes in the canine mammary gland.
Faustino
A M R
AM
Instituto Anatomica Patologica e Patologia Aviare, Veterinary Faculty of Milan, Italy.
van Garderen
E
E
Schalken
J A
JA
Nederbragt
H
H
D000236:Adenoma / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001485:Basement Membrane / Q000737:chemistry / Q000378:metabolism; D002277:Carcinoma / Q000378:metabolism* / Q000556:secondary; D002809:Chondroitin Sulfates / Q000096:biosynthesis; D004283:Dog Diseases / Q000378:metabolism* / Q000473:pathology; D004285:Dogs; D005109:Extracellular Matrix / Q000737:chemistry / Q000378:metabolism; D005260:Female; D006965:Hyperplasia / Q000662:veterinary; D007150:Immunohistochemistry / Q000662:veterinary; D008321:Mammary Glands, Animal / Q000033:anatomy & histology / Q000378:metabolism* / Q000473:pathology; D015674:Mammary Neoplasms, Animal / Q000378:metabolism* / Q000473:pathology; D011230:Precancerous Conditions / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D019063:Tenascin / Q000096:biosynthesis*
D019063:Tenascin; D002809:Chondroitin Sulfates